MARKET

VINCU

Vincerx Pharma Inc
VINCU
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-13.2256
-
6.55
177,221,709.00
BRIEF-Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/Cdk9 Inhibitor Vip152 In Lymphoma
reuters.com · 06/10 12:10
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and car...
GlobeNewswire · 06/10 12:00
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-...
Benzinga · 06/07 18:11
Small Cap Biotech Vincerx Cuts Third Of Staff
Cancer-focused biotech Vincerx Pharma Inc (NASDAQ: VINC) would lay off 33% of its staff to get its lead program through two Phase I studies. The move comes a little less than two years after Vincerx went public via a SPAC and its stock fell more than 80% i...
Benzinga · 06/07 12:25
Vincerx Pharma, Inc. (NASDAQ:VINC) up 10%, but insiders are still down 85% after purchasing US$806k of stock last year
Insiders who purchased US$806k worth of Vincerx Pharma, Inc. ( NASDAQ:VINC ) shares over the past year recouped some of...
Simply Wall St. · 06/06 10:24
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual Meeting Continues to execute on Phase 1b VIP152 clinical studies; o...
GlobeNewswire · 05/12 20:05
Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic cancers PALO ALTO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Vincerx ...
GlobeNewswire · 04/08 17:05
BRIEF-Vincerx Pharma Posts Quarterly Loss Per Share $0.31
reuters.com · 03/29 12:12
More
No Data
Learn about the latest financial forecast of VINCU. Analyze the recent business situations of Vincerx Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-1.14-0.89-0.65-0.40
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 22
Institutional Holdings: 1.85M
% Owned: 28.24%
Shares Outstanding: 6.56M
TypeInstitutionsShares
Increased
1
248
New
1
110
Decreased
0
0
Sold Out
8
2.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data

Webull offers kinds of Vincerx Pharma Inc stock information, including NASDAQ:VINCU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VINCU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VINCU stock methods without spending real money on the virtual paper trading platform.